{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000086","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.722842+00:00","generated_at":"2026-05-19T10:40:00.583496+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025","bullets":["ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.","ORR 84.2% in WM (n=19 evaluable); included 10.5% VGPR, 57.9% PR; IgM reductions >90% in three patients.","Well tolerated across 50-600 mg doses; common AEs low-grade purpura/contusion (45.8%), neutropenia (29.2%); no new atrial fibrillation.","Patients heavily pretreated: median 4 prior lines, 97.9% prior BTKi, 83.3% prior BCL2i; responses seen regardless of baseline mutations or CNS involvement.","Nurix on track to initiate pivotal trials of bexobrutideg in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000086","json":"https://secwatch.observer/filing/0001549595-25-000086.json","markdown":"https://secwatch.observer/filing/0001549595-25-000086.md","text":"https://secwatch.observer/filing/0001549595-25-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000086/0001549595-25-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000086/nrix-20250612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T10:40:00.583496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}